RAS inhibitors in hypertension
Pro Research Analysisby 
Searched over 200M research papers
RAS Inhibitors in Hypertension: Mechanisms and Drug Classes
Renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARBs), and direct renin inhibitors, are widely used to manage hypertension. These drugs work by blocking different steps in the RAS pathway, which plays a key role in blood pressure regulation and the development of hypertension-related organ damage. ACE inhibitors and ARBs are the most commonly prescribed, while direct renin inhibitors like aliskiren are newer options with proven efficacy in lowering blood pressure 16.
Efficacy Compared to Other Antihypertensive Drug Classes
Large-scale studies and systematic reviews show that RAS inhibitors are as effective as other first-line antihypertensive drugs (such as thiazide diuretics, calcium channel blockers, and beta-blockers) in reducing all-cause mortality in people with hypertension 23. However, there are some differences in specific outcomes:
- Compared to calcium channel blockers, RAS inhibitors reduce the risk of heart failure but slightly increase the risk of stroke 23.
- Compared to thiazide diuretics, RAS inhibitors are associated with a higher risk of heart failure and stroke, but similar rates of death and heart attacks 23.
- Compared to beta-blockers, RAS inhibitors may reduce the risk of stroke and total cardiovascular events, but the evidence is of lower quality 23.
Organ Protection and Special Indications
RAS inhibitors offer benefits beyond blood pressure reduction. They are particularly effective in preventing or delaying the development of diabetes and provide better protection for organs such as the kidneys, heart, and blood vessels compared to some other antihypertensive agents 14. These drugs are especially recommended for patients with diabetes, impaired kidney function, proteinuria, left ventricular dysfunction, recent myocardial infarction, or multiple cardiovascular risk factors 147.
Target Organ Damage and Cardiovascular Outcomes
RAS inhibitors help prevent or delay target organ damage, such as left ventricular hypertrophy, chronic kidney disease, and atherosclerosis, by blocking the harmful effects of angiotensin II . ACE inhibitors tend to have stronger heart-protective effects, while ARBs may offer better neuroprotection . Both classes reduce the risk of cardiovascular and renal events in hypertensive patients .
Tolerability and Side Effects
RAS inhibitors are generally well tolerated, with a favorable side effect profile compared to other antihypertensive drugs . The main limitation of ACE inhibitors is the risk of cough and, rarely, angioedema. Patients who are elderly, volume-depleted, or on high doses of diuretics may be at higher risk for low blood pressure or kidney function decline .
Novel and Emerging Therapies Targeting the RAS
Research is ongoing to develop new therapies that target additional components of the RAS, such as aminopeptidase A inhibitors, which act on the brain RAS and show promise in animal models 59. Other novel approaches include dual-acting agents, gene therapy, and drugs that enhance the protective ACE2/angiotensin-(1-7)/Mas axis . These strategies aim to improve blood pressure control and reduce side effects.
RAS Inhibitors in Special Populations
RAS inhibitors are particularly recommended for hypertensive patients with diabetes, cardiovascular disease, or impaired renal function, as they reduce the risk of death, cardiovascular events, and kidney dysfunction in these groups . In patients with hypertension and COVID-19, RAS inhibitors may improve clinical outcomes by reducing disease severity and supporting immune function .
Clinical Practice and Outcomes
Persistence with RAS inhibitor therapy is higher in hypertensive patients, especially after events like myocardial infarction, and is associated with better survival rates . Combined use of ACE inhibitors and ARBs may offer additional organ protection in some cases, but should be considered carefully due to potential risks 16.
Conclusion
RAS inhibitors are a cornerstone in the management of hypertension, offering effective blood pressure control, organ protection, and favorable outcomes in high-risk patients. While their overall impact on mortality is similar to other antihypertensive drugs, they provide unique benefits for patients with diabetes, kidney disease, and cardiovascular risk. Ongoing research into novel RAS-targeted therapies may further improve hypertension management in the future 1234+3 MORE.
Sources and full results
Most relevant research papers on this topic
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
First-line RAS inhibitors show no significant advantage over other first-line antihypertensive drugs in reducing cardiovascular events and death in people with hypertension.
Effects of inhibition of the renin-angiotensin system on hypertension-induced target organ damage: clinical and experimental evidence.
Inhibiting the renin-angiotensin system (RAS) through ACE-inhibitors and ARBs reduces cardiovascular risk and prevents or delays target organ damage in hypertensive patients.
Recommended Management of Hypertensive Patients with Diabetes for Renin-Angiotensin System (RAS) Inhibitors
RAS inhibitors are recommended as a first-line treatment for hypertensive patients with diabetes, cardiovascular disease, and impaired renal function due to their lower relative risk compared to other antihypertensive agents.
DOI